Clinical Trial Update: Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial by the National Cancer Institute is evaluating the combination of Peposertib (M3814) and Tuvusertib (M1774) in patients with advanced, metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors
• Unresectable Solid Tumors

Drugs mentioned

• Peposertib (Peposertib)
• Tuvusertib (tuvusertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Status: RECRUITING